John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4 antibody-drug conjugates such as puxitatug samrotecan are emerging as options for relapsed/metastatic disease.
Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III randomized OPTIMA trial, which is comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment with estrogen receptor (ER)-positive, HER2-negative early breast cancer (Abstract 500).
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6 study of chemoimmunotherapy in HER2-negative advanced gastric/gastroesophageal junction (GEJ) cancer (Abstract 4006); and an investigational EP4 antagonist in combination with chemoimmunotherapy as a first-line strategy for HER2-negative gastric/GEJ cancer (Abstract 4007).
Jessica J. Lin, MD, Mass General Brigham Cancer Institute, presents data from the ALKOVE-1 study, which is looking at the investigational ALK tyrosine kinase inhibitor (TKI) neladalkib among patients with ALK-positive non–small cell lung cancer (NSCLC); Dr. Lin discusses the first analyses of phase II TKI-pretreated patients and preliminary data in TKI-naive patients (Abstract 8503).
Jason R. Westin, MD, FASCO, of The University of Texas MD Anderson Cancer Center, provides an update on the safety and efficacy data from the phase III SUNMO trial, which compared mosunetuzumab and polatuzumab vedotin vs rituximab, gemcitabine, and oxaliplatin in patients with relapsed or refractory large B-cell lymphoma (LBCL) (Abstract 7007).
